The role of electronegative low-density lipoprotein in cardiovascular diseases and its therapeutic implications

Basit Öğe Kaydı
dc.authoridKe, Liang-Yin/0000-0002-2547-0987
dc.contributor.authorAkyol, Sumeyya
dc.contributor.authorLu, Jonathan
dc.contributor.authorAkyol, Omer
dc.contributor.authorAkcay, Fatih
dc.contributor.authorArmutcu, Ferah
dc.contributor.authorKe, Liang-Yin
dc.contributor.authorChen, Chu-Huang
dc.date.accessioned2025-10-24T18:09:11Z
dc.date.available2025-10-24T18:09:11Z
dc.date.issued2017
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractCardiovascular disease (CVD) is a health problem of great concern to both the public and medical authorities. Low-density lipoprotein (LDL) has been reported to play an important role in both the development and progression of CVD, but studies are underway to determine how LDL exerts its effects. In recent years, it has been found that LDL has several subfractions, each of which affects endothelial function differently; L5, the most electronegative fraction, has been shown to be unique in that it induces an atherogenic response. This review examines the current knowledge concerning the relationships between L5 and CVD and highlights the role of L5 in the pathophysiology of CVD, especially with regards to atherosclerosis.
dc.description.sponsorshipTUBITAK Scientist Support Directorate-International Postdoctoral Research Fellowship Program [BIDEB-2219, 1059B191401803, 1059B191401533]; Kaohsiung Medical University [KMU-TP104D00]; Kaohsiung Medical University Hospital [KMUH103-10V03]; Vascular and Medicinal Research Fund, Texas Heart Institute [765-64050]
dc.description.sponsorshipSumeyya Akyol, PhD, and Omer Akyol, MD, PhD, are supported by the TUBITAK Scientist Support Directorate-International Postdoctoral Research Fellowship Program (BIDEB-2219) (Fellowship no: S.A. - 1059B191401803, O.A. - 1059B191401533). Additional funding was provided by the Kaohsiung Medical University (grant KMU-TP104D00), the Kaohsiung Medical University Hospital (grant KMUH103-10V03), and the Vascular and Medicinal Research Fund, Texas Heart Institute (765-64050).
dc.identifier.doi10.1016/j.tcm.2016.11.002
dc.identifier.endpage246
dc.identifier.issn1050-1738
dc.identifier.issue4
dc.identifier.pmid28040327
dc.identifier.scopus2-s2.0-85009861375
dc.identifier.scopusqualityQ1
dc.identifier.startpage239
dc.identifier.urihttps://doi.org/10.1016/j.tcm.2016.11.002
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3495
dc.identifier.volume27
dc.identifier.wosWOS:000400323700003
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Science London
dc.relation.ispartofTrends In Cardiovascular Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20251023
dc.subjectL5; Cardiovascular disease; Electronegative low-density lipoprotein
dc.titleThe role of electronegative low-density lipoprotein in cardiovascular diseases and its therapeutic implications
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu